Volociximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | α5β1 integrin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6434H9942N1706O2040S52 |
| Molar mass | 145501.33 g·mol−1 |
  (what is this?) (verify) | |
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
It is thought to reduce metastases. Early results show potential in renal cell cancers.[citation needed]
References
- ^ Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW (January 2010). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients". Cancer Chemotherapy and Pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731. S2CID 23035675.
External links
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Short description with empty Wikidata description
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs